Search
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the spo...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesAxitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalAxitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumo...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of formi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: BEN SPAL-P® 25Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalDeferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). It was developed to address the significant unmet medical need i...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpiv...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated b...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLedipasvir
go.drugbank.com/drugs/DB09027ApprovedLedipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates